The purpose of our study was to investigate the morphology and distribution of calcifications initially interpreted as benign or probably benign, but proven to be malignant by subsequent stereotactic biopsy, and to identify the reason for misinterpretation or underestimation at the initial diagnosis. Materials and Methods: Out of 567 women who underwent stereotactic biopsy for calcifications at our hospital between January 2012 and December 2014, 167 women were diagnosed with malignancy. Forty-six of these 167 women had previous mammography assessed as benign or probably benign which was changed to suspicious malignancy on follow-up mammography. Of these 46 women, three women with biopsy-proven benign calcifications at the site of subsequent cancer were excluded, and 43 patients were finally included. The calcifications (morphology, distribution, extent, associated findings) in the previous and follow-up mammography examinations were analyzed according to the Breast Imaging Reporting and Data System (BI-RADS) lexicon and assessment category. We classified the patients into two groups: 1) group A patients who were still retrospectively re-categorized as less than or equal to BI-RADS 3 and 2) group B patients who were re-categorized as equal to or higher than BI-RADS 4a and whose results should have prompted previous diagnostic assessment. Results: In the follow-up mammography examinations, change in calcification morphology (n = 27, 63%) was the most frequent cause of assessment change. The most frequent previous mammographic findings of malignant calcification were amorphous morphology (n = 26, 60%) and grouped distribution (n = 36, 84%). The most frequent calcification findings at reassessment were amorphous morphology (n = 4, 9%), fine pleomorphic calcification (n = 30, 70%), grouped distribution (n = 23, 53%), and segmental calcification (n = 12, 28%). There were 33 (77%) patients in group A, and 10 patients (23%) in group B. Conclusion: Amorphous morphology and grouped distribution were the most frequent mammographic findings of calcifications that were misinterpreted or underestimated by the initial radiologist and confirmed as malignancy at follow-up. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
INTRODUCTION
variability of BI-RADS usage, calcification descriptors were inconsistently used among the readers (2) . Moreover, a large retrospective review has indicated that two-thirds of all calcifications referred for biopsy are described as "pleomorphic" (3), which is a rather ambiguous term that relies on the intuition of the radiologist.
Malignant breast lesions that initially have a "probably benign" mammographic appearance should be promptly identified with a short-term mammographic follow-up (4), but perception er- In our present study, we carefully investigated the mammographic findings of calcifications that were missed or misinterpreted at initial mammography and subsequently diagnosed as malignant after stereotactic biopsy on follow up mammography.
MATERIALS AND METHODS

Patient Selection
Our Institutional Review Board approved this retrospective study and waived the requirement for informed consent.
We used the examination code for stereotactic core biopsy to search through our Picture Archiving and Communication System for the records of patients who underwent this biopsy procedure from January 2012 to December 2014. Stereotactic biopsy was performed with 11-gauge vacuum probes (Mammotome;
Ethicon Endo-Surgery, Cincinnati, OH, USA) on an upright stereotactic digital unit using the Senographe Essential Stereotaxy machine (General Electric Medical Systems, Milwaukee, WI, USA). After a mean number of 12 specimens per biopsy had been retrieved using this procedure, specimen radiography was performed to confirm the inclusion of representative calcifications.
Of the 567 patients who had undergone a stereotactic core biopsy for calcifications, 167 women were diagnosed with malignancy in the final pathologic records. The inclusion criteria for our study were as follows: patients whose calcifications on mammography were initially diagnosed as benign or probably benign and subsequently changed to suspicious malignancy during follow-up mammography and whose final biopsy or surgical pathologic results revealed a malignancy. Forty-six patients who met our inclusion criteria were selected, although three patients with an existing biopsy-proven benign pathology were excluded later. Finally, 43 patients, all asymptomatic, ranging in age from 31 to 72 years (mean, 51.1 years), were included in our analyses.
Mammographic Evaluation
All mammography examinations were performed using the The readers recorded the mammographic findings (Table 1) and assessment categories of the initial mammography described previously by the initial radiologists, and then they re-analyzed the calcification and re-categorized the initial mammography according to the BI-RADS classification to identify the most likely reason for the misinterpretation or underestimation of calcifications. We also analyzed how the mammographic findings of calcifications later changed on the follow-up diagnostic examination to being suggestive of suspicious malignancy. Three additional radiologists with 5 years' experience in breast imaging, and who were blinded to patient's information and the followup mammography, were involved in BI-RADS re-categorization of the initial mammography. Finally, we classified the patients into two groups: 1) group A: patients who were still retrospectively re-categorized as less than or equal to BI-RADS 3, and 2) group B: patients who were re-categorized as equal to or higher than BI-RADS 4a and whose results should have previously prompted subsequent diagnostic assessment. If more than three radiologists agreed for recall of the initial mammographic finding, the patients were assigned to 'group B' .
The time between the initial mammographic detection and tissue diagnosis was determined by calculating the time from the initial follow-up recommendation to the time of the biopsy recommendation.
Statistical Analysis
A two-sample t-test was used to assess the relationship between malignancy and the difference in extent of calcification between the previous and follow-up mammography examinations and between the surgical method (breast conserving operation or total mastectomy) and the difference in calcification.
A p value less than 0.05 was considered to indicate a statistically significant difference.
RESULTS
The mean interval between the initial follow-up recommendation and the subsequent biopsy recommendation for 43 malignancies was 13.6 months (range, 4-69 months). At least a 6-month mammographic follow-up was performed for 4 of the 43 lesions (9%), follow-up within 12 months was performed for 17 lesions (40%), follow-up within 2 years was performed for 18 lesions (42%) and follow-up for more than 2 years was performed for 4 lesions (9%). Of these 43 lesions, according to the pathologic examination, 35 (82%) were ductal carcinomas in situ or ductal carcinomas in situ with microinvasion, 5 (12%) were 33 (77%) patients with calcifications that were evident in retrospect but they were not thought to be suspicious and were re-categorized as less than or equal to BI-RADS 3 (group A).
Ten patients (23%) had clearly abnormal findings that were atypical and suggestive of cancer and they were re-categorized as equal to or higher than BI-RADS 4a (group B, which represented 'misinterpreted or overlooked').
In group A, out of the 33 patients assessed as 'benign or probably benign' by the initial interpreting radiologist, 20 (61%)
showed amorphous morphology and 29 (88%) had grouped distribution of calcifications ( Fig. 1) on the initial mammography. Among these 33 patients, fine pleomorphic (25/33, 76%) morphology and grouped (19/33, 58%) distribution were assessed as suspicious malignancy on follow up mammography prior to biopsy (Table 2) . In group B, out of the 10 patients who were 'misinterpreted or overlooked' by the initial radiologist, 6
cases (60%) showed amorphous morphology and 7 cases (70%)
showed grouped calcifications on the initial mammography (Fig. 2) . Among these 10 patients, fine pleomorphic (5/10, 50%) morphology and grouped (4/10, 40%) distribution were assessed as suspicious malignancy on follow up mammography prior to biopsy ( Table 3) . Analysis of previous and follow-up mammography for cancers in both groups showed that a change in calcification morphology (n = 27, 63%), distribution (n = 3, 7%), or both (n = 13, 30%) were the most frequent reasons for the assessment change.
Most calcifications did not show any associated findings (34/43, 79%); out of the remaining patients, eight patients (19%)
presented with asymmetry and one patient (2%) presented with architectural distortion on the previous and follow-up mammography. Finally, retrospective reassessment of the BI-RADS category showed that the previous mammography identified five patients with BI-RADS category 2; all with punctate morphology with grouped distribution, and twenty-eight patients with BI-RADS category 3 in group A, and two patients with BI-RADS 4b category and eight patients with BI-RADS 4a category in group B. In the follow-up mammography prior to stereotactic biopsy, all patients were categorized as equal to or higher than BI-RADS category 4a (Fig. 3) . In group A, 26 (79%) ductal carcinomas in situ or ductal carcinomas in situ with microinvasion and 7 (21%) invasive cancers were diagnosed pathologically, and in group B, 9 (90%) ductal carcinomas in situ or ductal carcinomas in situ with microinvasion and 1 (10%) invasive cancer were diagnosed pathologically. In group A, all five pa- More than half of the cancers in our study were amorphous (60%) or grouped (84%) calcifications in the initial mammography and were assessed as suspicious malignancy in the follow-up mammography as 30 fine pleomorphic (70%) and 23 grouped (53%) calcifications. Mammographically amorphous calcifications have been considered indeterminate with variable recommendations for follow-up or biopsy. Amorphous calcifications are considered punctate and followed up by one radiologist or pleomorphic and subject to biopsy by another (10) . They have also been described as "sufficiently small or hazy that a more specific morphologic classification cannot be made" (1) . In a prior study by Liberman et al. (3) , 74% of all segmentally distributed calcifications and 68% of those in a linear distribution proved malignant compared with 36% of grouped calcifications. In the current study, we found a significant percentage of malignancies with grouped distribution of calcifications: 58% (19/33) in group A were grouped calcifications and 40% (4/10) in group B were grouped calcifications. We realized that radiologists often consider a higher than expected percentage of "grouped" calcifications to be "probably benign" or less than a BI-RADS category 3.
A BI-RADS category 3, the "probably benign" finding, is suggested for lesions with a low likelihood of malignancy (risk of malignancy < 2%) that do not require immediate biopsy. It has been reported that a small percentage of lesions assigned to the probably benign group that are actually malignant should be rapidly identified-within 6-12 months-by a change in appearance at subsequent imaging (12) . The mean time to biopsy of malignant lesions in our study was 13.6 months (range, 4-69 months). In the Sickles study (4), almost all cancers were identified by a change in the mammographic appearance at a 6-or Thus, assigning a category based on BI-RADS descriptors involves subjective interpretation by the radiologist (11) . One previous study evaluated mammography performance and found that "discordant recommendations" were evident for mammograms classified as probably benign and that 46% of interval cancers had been assessed as probably benign (13) . In the current study, the previous radiologist described "suspicious" calcifications but finally regarded them to be BI-RADS 3 and recommended short-term follow-up rather than stereotactic biopsy. BI-RADS lexicon rather than on the individual interpretation of the radiologist, and our study underscores the importance of identifying malignancies among benign-appearing lesions on mammography.
There were several limitations to our present study. First, our analyses were retrospective and although two radiologists reviewed the images in consensus, we did not evaluate interobserver variability. Second, at the initial mammography, the interpreting radiologist did not examine the magnification view and a 6-month or 1-year follow up was recommended and this omission may have caused an 'interpretation error' . Third, there is a possibility of a sample-selection bias since we did not analyze patients initially assigned as "benign or probably benign" on mammography and diagnosed as pathologically benign. Fourth, we had a limited number of patients, which potentially limits the general applicability of our findings.
In conclusion, we observed that on mammography more than half of breast cancers manifest as amorphous or grouped calcifications. It is unavoidable that radiologists occasionally miss or misinterpret subtle mammographic findings. However, it is worth emphasizing that the "benign or probably benign" category should be assessed based on the BI-RADS lexicon and assessment category and an effort should be made to follow up patients more closely, thus, decreasing the incidence of delayed diagnosis of breast cancer while at the same time decreasing unnecessary breast biopsies.
